Price
Target price
€7.48
€7.48
2.950%
0.214
2.950%
€49.86
20:32 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc gained 2.950% today.
The stock is one of the favorites of our community with 24 Buy predictions and 3 Sell predictions.
Based on the current price of 7.48 € the target price of 49 € shows a potential of 555.43% for Intellia Therapeutics Inc which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Intellia Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 2.950% | 16.155% | 0.721% | -65.485% | -36.102% | -84.634% | -59.328% |
| Chromadex Corp | 17.770% | -2.475% | 27.922% | 281.783% | 91.262% | 357.927% | 143.812% |
| Polynovo Ltd | 2.130% | 2.174% | -11.321% | -48.162% | -41.736% | -7.237% | -57.012% |
| Cardio3 Biosciences S.A. | -7.690% | -1.763% | -6.024% | 45.794% | -40.998% | -77.765% | -96.293% |
Comments
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the